Statement by Sung Poblete, PhD, RN, CEO of FARE, Regarding AstraZeneca’s Decision to Cap the Cost of Inhalers
“At FARE, we applaud AstraZeneca’s decision to cap the cost of its inhalers, setting a standard for affordability in healthcare that we hope is emulated by other companies. Many in the asthma patient community also live with the disease of food allergy and so at the same time we offer these thanks, we urge the industry and government to do what is necessary to improve patient access to epinephrine auto-injectors by capping the cost in similar fashion so that those more than 33 million people in the US with food allergies can move more safely through the world and afford their medication.”
Media Contact:
About FARE
FARE (Food Allergy Research & Education) is the leading nonprofit organization that empowers the food allergy patient across the journey of managing their disease. FARE delivers innovation by focusing on three strategic pillars—advocacy, research, and education—united by the through line of health equity. FARE’s initiatives accelerate the future of food allergy through effective policies and legislation, novel strategies toward prevention, diagnosis, and treatment, and building awareness and community. For more information, visit FoodAllergy.org.